Genmab Foundations Firm Amid Share Price Slumps

The Danish drugmaker's stock keeps falling as investors wait to see if Johnson & Johnson will opt in to co-develop a successor to the partners' multiple myeloma big earner Darzalex, but analysts have been heralding Genmab's bright prospects for assets such as Epkinly and Rina-S.